U Wagner
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
05.07.2011Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
05.07.2011Gynecol Oncol 2011; 123:27-32
Baumann K, Lück H J, Vergote I, Schmalfeldt B, Huober Jens, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
Harter P, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Annals of surgical oncology 2009; 16:1324-30.
01.05.2009Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
01.05.2009Annals of surgical oncology 2009; 16:1324-30
Harter P, Loibl S, Meier W, Huober Jens, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H J, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A
The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Journal of cancer research and clinical oncology 2002; 128:153-60.
01.03.2002The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
01.03.2002Journal of cancer research and clinical oncology 2002; 128:153-60
Huober Jens, Meyer A, Wagner U, Wallwiener D
Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken
Huober J, Wagner U, Wallwiener D. Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken. Geburtsh Frauenheilk 2002; 62:15-21.
01.01.2002Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken
01.01.2002Geburtsh Frauenheilk 2002; 62:15-21
Huober Jens, Wagner U, Wallwiener D
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H, Schlebusch H, Renke K, Huober J, Giffels P, Reinartz S, Köhler S, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62.
01.05.2001Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
01.05.2001Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H J, Schlebusch H, Renke K, Huober Jens, Giffels P, Reinartz S, Köhler S, Wallwiener D
Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
Huober J, Meyer A, Wagner U, Wallwiener D. Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom. Med. Welt 2001; 52:101-105.
01.01.2001Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
01.01.2001Med. Welt 2001; 52:101-105
Huober Jens, Meyer A, Wagner U, Wallwiener D
Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
Huober J, Meyer A, Wagner U, Wallwiener D. Qualitätssicherung in der operativen Theraphie von Ovarialtumoren. Med. Welt 2001; 52:184-187.
01.01.2001Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
01.01.2001Med. Welt 2001; 52:184-187
Huober Jens, Meyer A, Wagner U, Wallwiener D
Die neoadjuvante endokrine Theraphie des Mammakarzinoms
Meyer A, Huober J, Krainick-Strobel U, Greb R, Wagner U, Wallwiener D. Die neoadjuvante endokrine Theraphie des Mammakarzinoms. Onkologe 2000; 1:67-71.
01.01.2000Die neoadjuvante endokrine Theraphie des Mammakarzinoms
01.01.2000Onkologe 2000; 1:67-71
Meyer A, Huober Jens, Krainick-Strobel U, Greb R, Wagner U, Wallwiener D